| [1] |
NISHIHARA K, KATSUMOTO F, KUROKAWA Y, et al. Anaplastic carcinoma showing rhabdoid features combined with mucinous cystadenocarcinoma of the pancreas[J]. Arch Pathol Lab Med, 1997, 121(10): 1104-1107.
|
| [2] |
IMAOKA H, IKEDA M, UMEMOTO K, et al. Comprehensive review of undifferentiated carcinoma of the pancreas: from epidemiology to treatment[J]. Jpn J Clin Oncol, 2023, 53(9): 764-773.
|
| [3] |
钱 波, 李 杨, 徐 敏. 胰腺未分化癌1例报道并文献复习[J]. 胃肠病学和肝病学杂志, 2018, 27(11): 1317-1320.
|
| [4] |
李皇保, 周 俊, 吴晓俊, 等. 胰腺癌病理类型: 基于美国SEER数据库的分析[J]. 中华肝胆外科杂志, 2018, 24(4): 258-262.
|
| [5] |
IMAOKA H, IKEDA M, MAEHARA K, et al. Risk stratification and prognostic factors in patients with unresectable undifferentiated carcinoma of the pancreas[J]. Pancreatology, 2021, 21(4): 738-745.
|
| [6] |
KIM K H, ROBERTS C W M. Mechanisms by which SMARCB1 loss drives rhabdoid tumor growth[J]. Cancer Genet, 2014, 207(9): 365-372.
|
| [7] |
MA Y Y, FENG J Y, DING D, et al. SMARCB1/INI1-deficient undifferentiated pancreatic carcinoma in a 13-year-old male patient: a case report[J]. Pediatr Blood Cancer, 2023, 70(3): e30038.
|
| [8] |
KOUCHI Y, SAKAI N, HARADA-KAGITANI S, et al. SMARCB1-deficient malignant neoplasm of the pancreas with heterogeneous morphologies that cannot be classified into existing histologic types[J]. Pathol Int, 2024, 74(12): 691-696.
|
| [9] |
MUGAANYI J, LU C J, LU C D, et al. Extended pancreato-duodenectomy coupled with adjuvant chemotherapy for SMARCB1/INI1 deficient pancreatic carcinoma: A case report and literature review[J]. Int J Surg Case Rep, 2021, 82: 105938.
|
| [10] |
AGAIMY A, HALLER F, FROHNAUER J, et al. Pancreatic undifferentiated rhabdoid carcinoma: KRAS alterations and SMARCB1 expression status define two subtypes[J]. Mod Pathol, 2015, 28(2): 248-260.
|
| [11] |
HUA Y N, SONI P, LARSEN D, et al. SMARCB1/INI1-deficient pancreatic undifferentiated rhabdoid carcinoma mimicking solid pseudopapillary neoplasm: a case report and review of the literature[J]. World J Gastroenterol, 2020, 26(36): 5520-5526.
|
| [12] |
LAND G, VAN HAERINGEN B, COOPER C, et al. A rare case of rhabdoid pancreatic carcinoma: prolonged disease-free survival following upfront resection and adjuvant chemotherapy[J]. Cureus, 2023, 15(12): e50145.
|
| [13] |
刘继煊, 李言言, 徐嘉雯. 胰腺“去分化”导管腺癌1例[J]. 临床与实验病理学杂志, 2024, 40(6): 669-671.
|
| [14] |
CHO Y M, CHOI J, LEE O J, et al. SMARCB1/INI1 missense mutation in mucinous carcinoma with rhabdoid features[J]. Pathol Int, 2006, 56(11): 702-706.
|
| [15] |
KAN M, KOUCHI Y, OHYAMA H, et al. Genomic analysis of undifferentiated carcinoma of the pancreas with squamous differentiation: A case report[J]. Cureus, 2024, 16(2): e55175.
|
| [16] |
AL-SHEHRI A, SILVERMAN S, KING K M. Squamous cell carcinoma of the pancreas[J]. Curr Oncol, 2008, 15(6): 293-297.
|
| [17] |
KRIDIS WBEN, KHANFIR A, TOUMI N, et al. Primary squamous cell carcinoma of the pancreas: a report of two cases and review of the literature[J]. Intern Med, 2015, 54(11): 1357-1359.
|
| [18] |
KEZLARIAN B E, LIN O, DOGAN S. SMARCB1-deficient carcinomas of the head and neck region: a cytopathologic characterization[J]. J Am Soc Cytopathol, 2020, 9(6): 494-501.
|
| [19] |
BRENCA M, ROSSI S, LORENZETTO E, et al. SMARCB1/INI1 genetic inactivation is responsible for tumorigenic properties of epithelioid sarcoma cell line VAESBJ[J]. Mol Cancer Ther, 2013, 12(6): 1060-1072.
|
| [20] |
PANCIONE M, REMO A, ZANELLA C, et al. The chromatin remodelling component SMARCB1/INI1 influences the metastatic behavior of colorectal cancer through a gene signature mapping to chromosome 22[J]. J Transl Med, 2013, 11: 297.
|
| [21] |
KOHASHI K, ODA Y. Oncogenic roles of SMARCB1/INI1 and its deficient tumors[J]. Cancer Sci, 2017, 108(4): 547-552.
|
| [22] |
DARR J, KLOCHENDLER A, ISAAC S, et al. Loss of IGFBP7 expression and persistent AKT activation contribute to SMARCB1/Snf5-mediated tumorigenesis[J]. Oncogene, 2014, 33(23): 3024-3032.
|
| [23] |
MUGAANYI J, LU C J, HUANG J, et al. Undifferentiated pancreatic carcinomas, clinical features and therapeutic options: what we know[J]. Cancers, 2022, 14(24): 6102.
|
| [24] |
ISHIGAMI K, NISHIE A, YAMAMOTO T, et al. Imaging features of undifferentiated carcinoma of the pancreas[J]. J Med Imaging Radiat Oncol, 2019, 63(5): 580-588.
|
| [25] |
孙心竹, 孙思予. 超声内镜在胰腺癌筛查中的作用[J]. 中国实用内科杂志, 2021, 41(5): 358-361.
|
| [26] |
SWAID M B, VITALE E, ALATASSI N, et al. Metastatic undifferentiated osteoclast-like giant cell pancreatic carcinoma[J]. Cureus, 2022, 14(8): e27586.
|
| [27] |
KING D A, RAHALKAR S, BINGHAM D B, et al. Pancreatic INI1-deficient undifferentiated rhabdoid carcinoma achieves complete clinical response on gemcitabine and nab-paclitaxel following immediate progression on FOLFIRINOX: a case report[J]. J Gastrointest Oncol, 2021, 12(2): 874-879.
|
| [28] |
LANZI C, ARRIGHETTI N, PASQUALI S, et al. Targeting EZH2 in SMARCB1-deficient sarcomas: Advances and opportunities to potentiate the efficacy of EZH2 inhibitors[J]. Biochem Pharmacol, 2023, 215: 115727.
|
| [29] |
CARUGO A, MINELLI R, SAPIO L, et al. p53 is a master regulator of proteostasis in SMARCB1-deficient malignant rhabdoid tumors[J]. Cancer Cell, 2019, 35(2): 204-220.e9.
|